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Correlates of Bacterial Vaginosis Over Long-Term Follow-Up:
Impact of HIV Infection
Leslie S. Massad,1 Charlesnika T. Evans,2 Raymond Kang,3 Anna Hotton,4 Ruth Greenblatt,5–7
Howard Minkoff,8 Kerry Murphy,9 Christine Colie,10 and Kathleen M. Weber11
Abstract
Correlates of bacterial vaginosis (BV) are poorly understood, especially in HIV infection. In a cohort study,
HIV-seropositive and comparison seronegative women were assessed every 6 months during 1994–2015. BV
was considered present when three of four Amsel criteria were met. Behavioral characteristics were assessed
using structured interviews. Multivariable logistic regression used generalized estimating equation models to
determine factors associated with BV. Cumulative incidence of BV over time was assessed using the log-rank
test. Among 3,730 women (964 HIV seronegative and 2,766 HIV seropositive) contributing 70,970 visits, BV
was diagnosed at 2,586 (14.0%) visits by HIV-seronegative women and 6,224 (11.9%) visits by HIV-
seropositive women ( p< .0001). The cumulative incidence of BV was 530/964 (55.0%) in HIV-seronegative
women and 1,287/2,766 (46.5%) in seropositive women ( p< .0001). In adjusted analyses, factors associated
with BV were younger age, ethnicity, lower income, less education, recruitment site, recruitment in the 2001–
2002 cohort, heavier drinking, current smoking, depression, and sex with a male partner; both hormonal
contraception and menopause were negatively associated with BV. Of 533 women with prevalent BV, 228
(42.8%) recurred within a year, while persistent BV was found in 12.8% of participants; neither proportion
differed by HIV serostatus. Time trends in the proportion of women with BV at any single visit were not
identified. BV is common among women with and at risk for HIV, but HIV infection does not predispose to BV,
which is associated instead with behavioral and cultural factors.
Keywords: HIV in women, bacterial vaginosis, Amsel criteria
Introduction
Bacterial vaginosis (BV) is a disruption in the normalbacterial ecology of the vagina, which is characterized
by a predominance of Lactobacillus species and a low vag-
inal pH. Women with BV have higher vaginal pH and more
diverse vaginal ecology, often with multiple Gram-negative
and anaerobic organisms that may form biofilms. BV is
common, affecting 10%–30% of women in the United States
annually.1 Factors associated with BV include specific sexual
and genital hygiene practices, especially douching and a
greater number of sexual partners,2,3 smoking and alcohol
consumption, and African-American ethnicity. In some stud-
ies, infection with the HIV has been linked to BV, while
condom and hormonal contraceptive use were associated with
lower BV risk. BV may be associated with increased HIV
replication4 and enhanced potential for HIV transmission.5
In the Women’s Interagency HIV Study (WIHS), we have
found differences in BV prevalence by method of diagnosis:
using clinically based Amsel criteria, BV was found in 18%
of HIV-seropositive women, versus 14% of seronegative
women ( p = .009). When the presence of BV was determined
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by Gram stain using Nugent criteria, which reflect microflora
changes, but do not require presence of discharge, BV was
more frequent and, in contrast, was found more often in HIV-
seronegative than HIV-seropositive women (42% vs. 48%,
p = .03).6 This difference suggests that subclinical distur-
bances in vaginal flora do not result from immunodeficiency,
but from other factors. Rates of BV decreased over time in
both groups, reaching a plateau of 30%–40% after some 4
years, and the decline among HIV-seropositive women was
associated with increasing use of combination antiretroviral
therapy.7
A number of gaps remain in the understanding of the
temporal dynamics of BV. The initial decline in BV preva-
lence within WIHS suggests that casefinding and therapy for
BV may be effective in reducing BV rates, although com-
peting factors, including advancing age, counseling, im-
provement in immune status after introduction of highly
effective antiretroviral therapy (HAART), and changes in
sexual behavior arising from disease awareness after enroll-
ment, may have played a role. The relatively high frequency
of BV across time suggests that BV remains a persisting
problem. Correlates of clearance and persistence are little
understood. We set out to explore BV frequency, clearance,
and persistence risk across time in both HIV-seropositive and
HIV-seronegative women.
Materials and Methods
The WIHS is a U.S. multicenter cohort study of health
outcomes among HIV-seropositive women. WIHS also
enrolled HIV-seronegative comparison women. Enrollment
began on October 3, 1994, at 6 study consortia and, over time,
has enrolled 4,068 women, including those enrolled during
expansions from 2001 to 2002 and 2011 to 2012. The study
was designed to ensure that the cohort reflected the evolving
HIV epidemic in U.S. women.8,9 At each site, human subject
committees reviewed and approved the study, and all par-
ticipants gave written informed consent. Follow-up contin-
ues, but this analysis includes information on BV through
March 31, 2015.
At semiannual visits, women completed health question-
naires with trained interviewers, had physical examinations,
including pelvic and speculum examinations, and had lab-
oratory specimens collected. Visits were scheduled when
participants were not menstruating, and women were in-
structed to avoid inserting any substance into the genital tract
for 48 h before each visit.
BV was diagnosed when samples met at least three of four
Amsel criteria (clue cells, pH >4.5, characteristic discharge,
and amine odor with KOH). Several BV outcomes were as-
sessed, including prevalence at recruitment, incidence, per-
sistence (presence at three or more visits), and BV at each
visit during the study time period. Demographic and medical
characteristics were obtained at baseline visit, including HIV
status, age, race/ethnicity, income, education, employment
status, and depression (CES-D score of 16 or higher on the
Center for Epidemiologic Studies Depression Scale). Base-
line behavioral factors were also recorded, including intake
of alcohol, smoking, injection drug use, number of sexual
partners in the prior 6 months, use of hormonal contraception,
menopause, and hysterectomy. BV was described by year and
by categorized time periods based on pre-HAART era (1994–
1995), introduction of HAART (1996–2000), and post-
HAART era (2001–2015). For HIV-seropositive women,
CD4+ T lymphocyte count (CD4 count), HIV RNA level, and
HAART use were assessed. Unadjusted (chi-square statistics
and independent sample t-tests) and adjusted analyses were
conducted to assess the association between demographic
and medical characteristics, and having BV at a given visit.
Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated and multivariable logistic regression was used
to determine factors independently associated with BV. To
control for repeated measurements within women, general-
ized estimating equation (GEE) multivariable logistic re-
gression models were fitted to obtain adjusted OR’s and
95% CI. All variables that were associated with BV in the
unadjusted analyses and factors associated with BV in the lit-
erature were included in preliminary multivariable models.
The most parsimonious model was selected, including only
variables that were significant in the final model. Cumulative
incidence of BV over time was assessed by HIV status using
incidence rate ratios (IRRs). Graphical displays of BV over
time are also described. All analyses were performed in the
SAS software, version 9.4 (SAS Institute, Inc., Cary, NC),
and STATA software, version 13.1 (StataCorp, College
Station, TX).
Results
After exclusions, we identified 3,730 women who had been
assessed in WIHS for BV, 964 HIV seronegative and 2,766
HIV seronegative. These women contributed 70,970 visits
(median of 19.0 visits/subject) at which BV was assessed by
Amsel criteria and followed for a total of 38,520 person-years
with a median follow-up of 11.2 person-years. Five percent
of the sample had only one visit at which BV was identified.
BV was found at 2,586 (14.0%) individual visits by HIV-
seronegative women and at 6,224 (11.9%) visits by HIV-
seropositive women ( p < .0001).
Table 1 shows the distribution of demographic, behavioral,
and medical variables among women who did and did not
have BV by visit. Table 1 also presents unadjusted and GEE-
adjusted ORs for the association of these variables with di-
agnosis of BV at any visit; we focused on adjusted results.
In these adjusted analyses, including both HIV-seropositive
and HIV-seronegative women, BV was not associated with
HIV status. When compared to visits that occurred before the
introduction of HAART into the cohort, visits during intro-
duction of HAART (1996–2000) were associated with the
identification of BV, while visits during the remaining study
period were not. Other factors that remained associated with
BV were younger age, ethnicity, especially non-Hispanic
black, income below $18,000/year, less than a high school
education, recruitment site, recruitment in the 2001–2002 co-
hort, more drinks per week, current smoking, depression, and
sex with a male partner in the prior 6 months; both hormonal
contraception and menopause were negatively associated with
BV (Table 1). Site and ethnicity were linked ( p< .0001), re-
flecting regional differences in U.S. demographic site.
In a separate model (Table 2), multivariable GEE analysis
for only HIV-positive women showed similar findings, ex-
cept there was no significant association with the time period
of introduction of HAART, and higher CD4 count was as-
sociated with lower risk BV.















































Further analysis demonstrated a significant time effect on
the interaction of HIV status and BV. Including an inter-
action term for timing of visit around introduction of
HAART into the cohort and HIV status demonstrated that in
HIV-seronegative women, BV diagnosis was more likely
during the 1996–2000 time period [adjusted OR (AOR) =
1.52, 95% CI 1.21–1.91, p = .0003], but not during the 2001–
2015 time period (OR = 1.08, 95% CI 0.82–1.41, p = .60),
when compared to the period before HAART introduction.
In HIV-seropositive women, compared to the 1994/1995
period, the prevalence of BV at each visit did not signifi-
cantly differ during the 1996–2000 (OR = 1.07, 95% CI
Table 1. HIV Status, Demographic Information, and Behaviors Among Women Assessed
for Bacterial Vaginosis Across 70,970 Visits
BV at visit
(n = 8,810), n (%)
No BV at visit
(n = 62,160), n (%)
Unadjusted




Seropositive 6,224 (70.7) 46,284 (74.5) 0.83 (0.79–0.87) <.0001 0.98 (0.88–1.09)
Seronegative 2,586 (29.3) 15,876 (25.5)
Visit timing
Pre-HAARTc (1994–1995) 595 (6.8) 3,942 (6.3) Reference <.0001 Reference
HAART initiation (1996–2000) 2,381 (27.0) 14,651 (23.6) 1.08 (0.98–1.19) 1.15 (1.03–1.28)
HAART (2001–2015) 5,834 (66.2) 43,567 (70.1) 0.89 (0.81–0.97) 0.90 (0.79–1.03)
Age (years)
<25 347 (3.9) 1,691 (2.7) Reference <.0001 Reference
25–34 2,401 (27.3) 12,078 (19.4) 0.97 (0.86–1.01) 0.94 (0.81–1.09)
35–44 3,779 (42.9) 23,675 (38.1) 0.78 (0.69–0.88) 0.79 (0.67–0.93)
45+ 2,283 (25.9) 24,716 (39.8) 0.45 (0.40–0.51) 0.64 (0.53–0.76)
Ethnicity
Non-Hispanic White 425 (4.8) 8,973 (14.4) Reference <.0001 Reference
Non-Hispanic African American 6,928 (78.6) 33,749 (54.3) 4.33 (3.92–4.79) 4.11 (3.39–4.97)
Hispanic 1,154 (13.1) 17,392 (28.0) 1.40 (1.25–1.57) 2.16 (1.74–2.69)
Other 303 (3.5) 2,046 (3.3) 3.13 (2.68–3.65) 2.51 (1.83–3.44)
Average household income <$18,000 6,050 (68.7) 39,314 (63.3) 1.27 (1.21–1.34) <.0001 1.10 (1.03–1.17)
Less than high school education level 3,434 (39.0) 22,770 (36.6) 1.11 (1.06–1.16) <.0001 1.18 (1.07–1.30)
Currently employed 2,794 (31.7) 22,553 (36.3) 0.82 (0.78–0.86) <.0001
Site/Location
Bronx, NY 1,014 (11.5) 13,998 (22.5) Reference <.0001 Reference
Brooklyn, NY 2,314 (26.3) 10,899 (17.5) 2.93 (2.71–3.17) 2.75 (2.36–3.20)
Washington DC 1,632 (18.5) 8,230 (13.2) 2.74 (2.52–2.97) 3.57 (3.07–4.15)
Los Angeles 299 (3.4) 11,994 (19.3) 0.34 (0.30–0.39) 0.51 (0.42–0.62)
San Francisco 2,021 (22.9) 9,168 (14.8) 3.04 (2.81–3.30) 2.57 (2.19–3.02)
Chicago 1,530 (17.4) 7,871 (12.7) 2.68 (2.47–2.92) 2.70 (2.34–3.12)
Recruitment wave
2001/2002 3,025 (34.3) 16,797 (27.0) 1.41 (1.35–1.48) <.0001 1.24 (1.11–1.40)
1994/1995 5,785 (65.7) 45,363 (73.0)
Number of drinks per week
None 3,880 (44.0) 34,974 (56.3) Reference <.0001 Reference
1–7 drinks/week 3,498 (39.7) 21,598 (34.7) 1.46 (1.39–1.53) 1.19 (1.11–1.27)
>7 drinks/week 1,432 (16.3) 5,588 (9.0) 2.31 (2.16–2.47) 1.50 (1.36–1.65)
Current smoker 5,398 (61.3) 27,946 (45.0) 1.94 (1.85–2.03) <.0001 1.40 (1.30–1.52)
Injection drug use since last visit 377 (4.3) 2,012 (3.2) 1.34 (1.19–1.50) <.0001
Male partner in last 6 months 6,917 (78.5) 38,726 (62.3) 2.21 (2.10–2.33) <.0001 1.50 (1.39–1.61)
Female partner in last 6 months 539 (6.1) 3,385 (5.5) 1.13 (1.03–1.24) .01
Used hormonal birth
control in last 6 months
551 (6.3) 4,649 (7.5) 0.83 (0.75–0.90) <.0001 0.80 (0.71–0.89)
Ever had hysterectomy 778 (8.8) 7,028 (11.3) 0.76 (0.70–0.82) <.0001
Reported having been
through menopause
1,360 (15.4) 16,562 (26.6) 0.50 (0.47–0.53) <.0001 0.69 (0.62–0.75)
Depressive symptoms
based on CES-D score (16+)
3,350 (38.0) 20,782 (33.4) 1.22 (1.17–1.28) <.0001 1.07 (1.01–1.14)
Unadjusted OR and 95% CIs and GEE-adjusted multivariable logistic regression.
ap-Values obtained using the chi-square test unless otherwise specified.
bResults reflect the most parsimonious GEE model. Blank cells reflect variables that were significant in unadjusted analyses, but were not
included in adjusted GEE analysis, because when included, they were not significant.
cHighly active antiretroviral therapy.
BV, bacterial vaginosis; CIs, confidence intervals; GEE, generalized estimating equation; HAART, highly effective antiretroviral
therapy; ORs, odds ratios.















































Table 2. Among HIV-Seropositive Women Only, Demographic Information and Behaviors












Pre-HAARTc (1994–1995) 481 (7.7) 3,119 (6.7) Reference <.0001 Reference
HAART initiation (1996–2000) 1,782 (28.6) 11,653 (25.2) 0.99 (0.89–1.10) 1.07 (0.95–1.21)
HAART (2001–2015) 3,961 (63.7) 31,512 (68.1) 0.82 (0.74–0.90) 0.88 (0.76–1.02)
Age (years)
<25 151 (2.4) 751 (1.6) Reference <.0001 Reference
25–34 1,640 (26.4) 8,078 (17.5) 1.01 (0.84–1.21) 0.98 (0.77–1.24)
35–44 2,801 (45.0) 18,146 (39.2) 0.77 (0.64–0.92) 0.79 (0.61–1.01)
45+ 1,632 (26.2) 19,309 (41.7) 0.42 (0.35–0.50) 0.63 (0.48–0.82)
Ethnicity
Non-Hispanic White 329 (5.3) 7,200 (15.6) Reference <.0001 Reference
Non-Hispanic African American 4,946 (79.5) 24,725 (53.4) 4.38 (3.90–4.91) 3.71 (2.99–4.61)
Hispanic 770 (12.4) 12,915 (27.9) 1.30 (1.14–1.49) 1.96 (1.52–2.54)
Other 179 (2.9) 1,444 (3.1) 2.71 (2.24–3.28) 2.24 (1.50–3.34)
Average household
income <$18,000
4,413 (70.9) 29,803 (64.4) 1.35 (1.27–1.43) <.0001 1.13 (1.05–1.22)
Less than high school
education level
2,441 (39.2) 17,305 (37.4) 1.08 (1.02–1.14) .005 1.16 (1.04–1.30)
Currently employed 1,726 (27.7) 15,304 (33.1) 0.78 (0.73–0.82) <.0001
Site/Location
Bronx, NY 624 (10.0) 9,727 (21.0) Reference <.0001 Reference
Brooklyn, NY 1,655 (26.6) 8,122 (17.5) 3.18 (2.88–3.50) 2.92 (2.44–3.49)
Washington DC 1,213 (19.5) 6,187 (13.4) 3.06 (2.76–3.38) 3.65 (3.04–4.37)
Los Angeles 168 (2.7) 9,260 (20.0) 0.28 (0.24–0.34) 0.39 (0.30–0.50)
San Francisco 1,386 (22.3) 6,784 (14.7) 3.18 (2.88–3.52) 2.72 (2.25–3.28)
Chicago 1,178 (18.9) 6,204 (13.4) 2.96 (2.67–3.28) 2.84 (2.40–3.37)
Recruitment wave
2001/2002 1,932 (31.0) 10,876 (23.5) 1.47 (1.38–1.55) <.0001 1.32 (1.14–1.51)
1994/1995 4,292 (69.0) 35,408 (76.5)
None 2,917 (46.9) 27,603 (59.6) Reference <.0001 Reference
1–7 drinks/week 2,404 (38.6) 15,204 (32.9) 1.50 (1.41–1.58) 1.22 (1.13–1.32)
>7 drinks/week 903 (14.5) 3,477 (7.5) 2.46 (2.26–2.67) 1.45 (1.29–1.63)
Current smoker 3,744 (60.2) 19,821 (42.8) 2.02 (1.91–2.13) <.0001 1.36 (1.24–1.49)
Injection drug use since last visit 377 (4.3) 2,012 (3.2) 1.34 (1.19–1.50) <.0001
Male partner in last 6 months 4,708 (75.6) 27,807 (60.1) 2.06 (1.94–2.19) <.0001 1.48 (1.36–1.61)
Female partner in last 6 months 324 (5.2) 1,956 (4.2) 1.24 (1.10–1.40) .0004
Used hormonal birth control
in last 6 months
354 (5.7) 3,104 (6.7) 0.84 (0.75–0.94) .002 0.82 (0.71–0.96)
Ever had hysterectomy 595 (9.6) 5,702 (12.3) 0.75 (0.69–0.82) <.0001
Reported having been
through menopause
1,021 (16.4) 13,229 (28.6) 0.49 (0.46–0.53) <.0001 0.69 (0.62–0.77)
Depressive symptoms based on
CES-D score (16+) reported
having been through menopause
2,512 (40.4) 16,033 (34.6) 1.28 (1.21–1.35) <.0001 1.11 (1.03–1.18)
CD4 lymphocyte count (cells/cm)
at visit, HIV-positive women only
<200 1,395 (22.4) 8,787 (18.9) Reference <.0001 Reference
200–500 2,722 (43.7) 18,620 (40.2) 0.92 (0.86–0.99) 0.94 (0.85–1.03)
>500 2,107 (33.9) 18,877 (40.8) 0.70 (0.65–0.76) 0.78 (0.70–0.87)
Log viral load at visit
(mean, median)
7.7, 7.9 6.7, 5.6 <.0001d, <0.0001e
Highly active antiretroviral
therapy use at visit
970 (15.6) 5,991 (12.9) 1.24 (1.15–1.34) <.0001
Unadjusted OR and 95% CIs and GEE-adjusted multivariable logistic regression.
ap-Value obtained by using the chi-square test unless otherwise specified.
bResults reflect the most parsimonious GEE model. Blank cells reflect variables that were significant in unadjusted analyses, but were not
included in adjusted GEE analysis, because when included, they were not significant.
cHighly active antiretroviral therapy.
dp-Value obtained by using the t-test for means.
ep-Value obtained by using the median two-sample test for medians.















































0.95–1.21, p = .28) and 2001–2015 (OR = 0.88, 95% CI
0.76–1.02, p = .09) time periods.
As shown in Figure 1, the cumulative incidence of new BV
diagnoses was higher in HIV-seronegative women (530/964,
55.0% vs. 1,287/2,766, 46.5%, p < .0001).
Prevalent BV was found at intake in 400 (14.5%) HIV-
seropositive women and 133 (13.8%) HIV-seronegative
women ( p = .61). Prevalent BV had a strong impact on sub-
sequent BV diagnosis. Of 533 women with prevalent BV, 228
(42.8%) had BV within a year; this proportion did not differ
by HIV serostatus. The incidence of BV was 22.2 cases/100
person-years among HIV-seropositive women and 24.7
cases/100 person-years among HIV-seronegative women
(IRR = 0.90, 95% CI 0.86–0.94). Excluding prevalent cases at
baseline, the overall incidence was slightly lower, but still
showed that HIV-seropositive women had a lower rate of
BV than HIV-seronegative women (20.8 vs. 23.4 cases/100
person-years, IRR = 0.86, 95% CI 0.85–0.93). Incidence was
higher among those with prevalent BV (4,2l7 cases/100
person-years) compared to those who did not have BV at
baseline (18.0 cases/100 person-years, IRR = 2.37, 95% CI
2.26–2.48).
As shown in Figure 2a, the proportion of women with BV
at any single visit ranged from 8.1% to 15.5%. This propor-
tion fell significantly across time, but in multivariable anal-
ysis, the effect was small (OR for each later year 0.98, 95%
CI 0.97–0.99). Figure 2b shows similar proportions by HIV
serostatus. In seronegative women, the proportion of BV at a
visit ranged from 10.0% to 18.6% ( p = .003) and was 7.0% to
14.6% in seropositive women ( p< .0001).
Persistent BV, defined as BV at three or more consecutive
visits, was found in 12.8% of participants and did not vary
by HIV serostatus ( p= .78). Only 64 women (1.7%, 18 HIV
seronegative and 1.9%, 46 HIV seropositive) had BV at every
visit assessed ( p= .67).
Discussion
BV was a common and recurring problem among the lar-
gely indigent and minority population enrolled in WIHS.
Although an earlier study found a decline over time in BV
rates diagnosed by Nugent criteria, in this expanded and
extended cohort study of HIV seropositive and comparison
seronegative women, BV was identified by Amsel criteria in
some 14% of women at baseline. This proportion remained
roughly constant throughout years of follow-up, ranging from
8% to 16%, although fewer than 2% of women had BV at
every visit. Only 13% of women studied had BV found at three
consecutive visits; conversely, 87% of women with BV had
resolution of one or more Amsel criteria and did not have
clinical BV 6–12 months after initial diagnosis. Roughly half
of the women studied had a diagnosis of BV during follow-up.
Recurrent BV was common among women with prevalent
BV, and 12.8% of women studied had BV persisting for at
least a year. Although fewer than 2% of women studied had
BV at every visit, and 5% had only one visit at which they
were assessed for BV, most women had BV identified at least
once, with cumulative incidence over 50%.
However, the cause of BV remains obscure and is likely
multifactorial. Etiologic factors include imbalances in the
FIG. 1. Cumulative incidence of bacterial vaginosis among HIV-seropositive and HIV-seronegative women.















































composition of the vaginal microbiota, possibly modulated
by sexual and hygienic practices. In our study, multivariable
analysis showed that HIV infection was not correlated with
BV, a finding discordant with results previously reported
from WIHS at baseline and during initial follow-up, as well
as from the HIV Epidemiology Research Study. This may
reflect selection among control HIV-seronegative women,
who were required to have behaviors placing them at risk for
HIV infection, which in turn might have predisposed to BV.
BV in the current study was linked to age, ethnicity, re-
cruitment site and year, smoking status, and sex with a male
partner. This suggests that disturbances in the vaginal mi-
croenvironment arising from hygienic and sexual practices
play a greater role in the development and persistence/
recurrence of BV than cellular immune factors. Differences in
cultural practices may explain why BV rates vary by ethnicity
and site. Consistent with this, Bradshaw et al. found that
recurrent BV occurs in more than 50% of cases within a year
and is linked with the same sexual partner and inconsistent
condom use, and reduced with oral contraceptive use.10
Further research may require more detailed studies of sexual
and genital hygiene behaviors linked to multiple BV assess-
ment strategies, while genome-wide association studies may
identify genetic components of risk.
FIG. 2. (a) The proportion
of women with at least three
of four Amsel criteria for
bacterial vaginosis across all 6-
month visits. (b) The percent-
age of HIV-seropositive and
HIV-seronegative women with
at least three of four Amsel
criteria for bacterial vaginosis
across all 6-month visits.















































Use of Nugent’s Gram stain criteria for the identification
of BV has some advantages over clinician assessment using
Amsel criteria, especially reproducibility. We chose to use
Amsel criteria to focus on women with clinical rather than
purely bacteriological findings. Compared to Nugent criteria,
diagnosis of BV by three of four Amsel criteria is 99% specific,
but only 37% sensitive for BV.11 More recently, nucleic acid
hybridization tests have become available to detect Gardner-
ella vaginalis. These are more sensitive than Amsel criteria,
but can require delay for reporting.12 Bacteriological changes
of subclinical BV are likely to be substantially more common
than we found and may persist longer than we report. In ad-
dition, bacteriological changes without clinically evident dis-
charge may be more common in HIV-seropositive women:
Jamieson and associates in another large U.S. cohort study of
women with HIV found that HIV infection was associated with
BV by Nugent criteria and risk for BV by Nugent criteria rose
as CD4 counts declined.13
Antibiotic therapies for BV appear to be effective, but
reversion to normal vaginal flora is often not durable. We
found that 43% of women with BV had another episode
within a year. Women are dissatisfied with current therapies
and use self-help and behavioral modification to minimize
risk, although some approaches such as douching may
increase risk, with minimal impact.14 Clinicians caring for
women with BV may consider home screening,15 probio-
tics,16 suppressive antibiotics, or the provision of antibiotics
to use when symptoms recur, to minimize delay arising from
need for a clinician visit.17
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